The Contracts Every Biotech Startup Needs (2026 Checklist)

Why a biotech startup needs tight contracts A biotech startup is almost entirely made of intellectual property and the agreements that secure it. The company often begins with science from a university, hires scientists who generate more IP, shares materials with collaborators, outsources research and manufacture, and raises money from investors who care deeply about whether the rights are clean. Each of those facts creates a contract, and a gap in any of them can sink a financing or a licensing deal years later. When ownership of a key invention is unclear, a material was used outside its permitted terms, or a founder leaves with know-how, the first question is what was agreed. Clear contracts answer that before diligence exposes the problem. This is a general checklist. The exact documents and wording depend on your country, your investors, and your science, so use it to find gaps rather than as final advice. ## Founding and IP ownership contracts Founder agreement and IP assignment. Records equity, vesting, roles, and, crucially, assigns to the company all IP the founders created for it. Missing or late founder IP assignment is one of the most common fatal findings in biotech diligence. University licence or spin-out agreement. Where the company is built on institutional research, the licence or assignment from the university sets the rights granted, field of use, royalties, diligence milestones, and what happens if milestones are missed. This is frequently the company's foundational asset. Employee and consultant IP-assignment and confidentiality agreements. Every scientist, advisor, and contractor must assign the IP they create and keep know-how confidential, because the company's value lives in that know-how. Scientific advisory board agreements. For advisors, covering confidentiality, IP, time commitment, and conflicts with their other roles. ## Research and collaboration contracts Sponsored research agreement. Where the company funds research at a university or institute, setting ownership of foreground results, publication rights, and the line between background and foreground IP. Research collaboration agreement. With another company or lab for joint work, allocating IP, cost, governance, and exclusivity. Material transfer agreement (MTA). For sending or receiving compounds, cell lines, antibodies, or samples, setting permitted use, onward-transfer limits, and rights in any results. Using material outside its MTA terms can create downstream ownership problems. Clinical research organisation (CRO) and manufacturing (CMO) agreements. As the company moves toward the clinic, outsourced research and manufacture need agreements covering scope, data ownership, regulatory duties, quality responsibilities, and audit rights. ## Commercial and financing contracts Licensing agreements (in and out). The deals that bring in or grant out rights to a molecule or platform, covering milestones, royalties, territory, field, diligence, and termination. For many biotechs an out-licence is the intended exit. Investment and shareholder agreements. Term sheets, subscription agreements, and shareholders agreements that govern funding rounds, board rights, protective provisions, and what happens on a sale. These carry representations about IP ownership, so the earlier contracts must line up. Grant agreements. Public or foundation grants come with conditions on use of funds, reporting, and sometimes rights in resulting IP, which can affect later commercial deals. ## Data, people, and operations Data processing and clinical-data agreements. Research and any clinical work generate personal and health data, so processors need data processing agreements and clinical data carries extra protection duties. Employment agreements. With strong confidentiality, IP assignment, and, where enforceable, reasonable restrictive covenants for key scientific staff. Lab lease, equipment, and insurance. Leases for lab and bench space, finance or leasing for specialist equipment, and appropriate insurance to track and renew. ## A short checklist to run against your startup - Have all founders, employees, and consultants signed IP-assignment and confidentiality agreements?

• Is the university licence or spin-out agreement in place, with its milestones and diligence terms understood and tracked?
• Is every material in or out covered by an MTA, with permitted use respected?
• Do CRO and CMO agreements fix data ownership, regulatory duties, and audit rights?
• Do investment documents' IP representations match the actual chain of assignments and licences?
• Are grant conditions on IP and reporting understood before they conflict with a commercial deal? ## Keeping the startup's contracts in one place For a biotech, the contract stack is the company. An investor's or acquirer's diligence will reconstruct the entire chain of IP from founders through the university licence, the MTAs, the research agreements, and the employment contracts, and a single missing assignment or a material used outside its terms can stall a round or cut a valuation. Too often these documents sit across a founder's inbox, a law firm's data room, and a shared drive, with nobody able to confirm quickly that the chain is clean. Drafting these documents, reviewing them for risky terms, tracking milestones and diligence obligations, and keeping a clean version history is really one connected job, and it is far easier when it lives in a single place. That one-workspace idea is what Adira is built around for business contracts, with per-clause risk visible and a built-in activity history, drafting and review running on Claude. Whatever tool you use, the checklist above holds: the startups that raise and exit cleanly are the ones whose contract chain is airtight before anyone goes looking. ## An honest note IP, research-contract, grant, data protection, and securities rules vary by country and investor, and the enforceability of IP assignments and restrictive covenants is fact-specific. Treat this as a map of what to have in place, then have the specific documents drafted or reviewed by qualified IP and corporate advisers for your situation. This is general information, not legal advice.